Bictegravir: all 44 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingNCT07708727Phase 2/3
• A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingNCT07645287Phase 2
• REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingNCT07476339Phase 4
• The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingNCT06375304Phase 4
• Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)CompletedNCT06104306Phase 4Results posted
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Active, not recruitingNCT05502341Phase 2/3Results posted
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingNCT05052996Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVCompletedNCT04143594Phase 2Results posted
• Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usECompletedNCT03998176Phase 4Results posted
• Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersCompletedNCT03960645Phase 1Results posted
• B/F/TAF Switch Study for HIV-HBV CoinfectionCompletedNCT03797014Phase 4Results posted
• Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsCompletedNCT03547908Phase 3Results posted
• B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected AdultsTerminatedNCT03532425Phase 4Results posted
• Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsCompletedNCT03405935Phase 3Results posted
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedCompletedNCT03110380Phase 3Results posted
• Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedNCT02652624Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607956Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607930Phase 3Results posted
• Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedCompletedNCT02603120Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedNCT02600819Phase 3Results posted
• Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal FunctionCompletedNCT02400307Phase 1Results posted
• Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02397694Phase 2Results posted
• Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected ParticipantsCompletedNCT02275065Phase 1Results posted
• A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)CompletedNCT07532304Phase 1
• Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruitingNCT07055451Phase 1
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Active, not recruitingNCT06630286Phase 3
• Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeNCompletedNCT06629480Not applicable
• Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Active, not recruitingNCT06532656Phase 2/3
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingNCT06333808Phase 3
• Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)CompletedNCT06177574Phase 4
• Doravirine and Weight Gain in Antiretroviral NaiveWithdrawnNCT05457530Phase 3
• Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of AgeStatus unknownNCT05147740Phase 4
• Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 InfectionActive, not recruitingNCT05122754Phase 4
• A Study of JNJ-56136379 in Healthy ParticipantsWithdrawnNCT04853524Phase 1
• Bictegravir/FTC/TAF for the Treatment of Primary HIV InfectionStatus unknownNCT04483674Phase 2
• Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsStatus unknownNCT04311957Phase 4
• Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedNCT04296695Phase 4
• Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIVTerminatedNCT04249037Phase 4
• Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based RegimenStatus unknownNCT04155554Phase 3
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically SuppressedStatus unknownNCT04132674Phase 4
• BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) StudyStatus unknownNCT03916328Phase 4
• Empiric Treatment for Acute HIV in the EDStatus unknownNCT03711253Phase 4
• Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1CompletedNCT03502005Phase 4
• Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)CompletedNCT03499483Phase 4

← Bictegravir overview